Kidney transplantation alone in end-stage renal disease patients with hepatitis B liver cirrhosis: a single-center experience

Transplantation. 2015 Jan;99(1):133-8. doi: 10.1097/TP.0000000000000234.

Abstract

Background: Kidney transplantation (KT) alone in end-stage renal disease (ESRD) patients with hepatitis B virus liver cirrhosis (LC) is controversial. This study compared outcomes of KT in hepatitis B surface antigen-positive patients with ESRD with (LC group) and without LC (non-LC group).

Methods: Outcomes were analyzed in 103 hepatitis B surface antigen-positive patients with ESRD who underwent KT alone between 1997 and 2011. Ninety-one were in the non-LC group and 12 were in the LC group. Of the latter, eight were Child-Pugh (CP) class A and four were CP class B.

Results: Baseline aspartate transaminase and alanine transaminase levels were higher in the LC group. model for end-stage liver disease (MELD) scores were similar in patients with CP class A and class B, only serum albumin level was lower in CP class B. After KT, one CP class A patient showed an increase in the CP score from 5 to 10 points, MELD score from 22.3 to 44.1 points. The CP and MELD scores of the other 11 patients in the LC group did not increase. All four pre-KT CP class B patients were reclassified as class A after KT because of elevated serum albumin levels. Four patients in the LC group developed hepatocellular carcinoma at a median of 35 months (range, 20-57 months) after KT. The 5-year patient survival rate was similar in the LC and non-LC groups (100% vs. 94%, P=0.15). The incidence of pre-KT LC did not differ between survivors and nonsurvivors (11% vs. 18%, P=0.61). Occurrence of hepatocellular carcinoma was significantly higher in nonsurvivors than in survivors.

Conclusion: Kidney transplantation alone may be safe in patients with compensated hepatitis B virus LC.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alanine Transaminase / blood
  • Aspartate Aminotransferases / blood
  • Biomarkers / blood
  • Carcinoma, Hepatocellular / virology
  • Female
  • Hepatitis B / complications*
  • Hepatitis B / diagnosis
  • Hepatitis B / mortality
  • Hepatitis B Surface Antigens / blood
  • Humans
  • Kaplan-Meier Estimate
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / mortality
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation* / adverse effects
  • Kidney Transplantation* / mortality
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / mortality
  • Liver Cirrhosis / virology*
  • Liver Neoplasms / virology
  • Male
  • Middle Aged
  • Republic of Korea
  • Retrospective Studies
  • Risk Factors
  • Serum Albumin / metabolism
  • Serum Albumin, Human
  • Time Factors
  • Treatment Outcome

Substances

  • ALB protein, human
  • Biomarkers
  • Hepatitis B Surface Antigens
  • Serum Albumin
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Serum Albumin, Human